Document is current
Any future updates will be listed below
-
Authors
Torfs, T.
Veltrop, R. J. A.
Lezzoche, G.
Heymans, S. R. B.
Verdonschot, J. A. J.
Nabben, M.
-
Funding
Funding for this research was provided by:
ZonMW / European Joint Programme on Rare Diseases (EJP RD) - JTC2022 “ProgerOmics”
European Union Commission, Seventh Framework Programme
Innovative Medicines Initiative 2 Joint Undertaking
European Innovation Council / European Commission
Dutch Research Council
Dutch Heart Foundation
Dutch Heart Foundation
- License Information
-
More Information
Article History
Received: 16 October 2025
Accepted: 20 November 2025
First Online: 2 February 2026
Declarations
:
: Heymans, S.R, B. receives personal fees for independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, Merck and CSL Behring, and receives research support from AstraZeneca and CSL Behring. Torfs, T., Veltrop, R.J.A., Lezzoche, G., Verdonschot, J.A.J., and Nabben, M. declare that they have no conflict of interest.
